Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Lockhart

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Therapeutic Drug Monitoring|December 1, 2004
Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometryBrian G Keevil, Sheila Newman, Stephen Lockhart, et al.
Vaccine|August 9, 2021
A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in IndiaJugesh Chhatwal, Amita Sapru, Balasubramanian Sundaram, et al.
Vaccine|July 28, 2020
Preventing infectious diseases for healthy ageing: The VITAL public-private partnership projectDebbie Van Baarle, Kaatje Bollaerts, Giuseppe Del Giudice, et al.
The Pediatric Infectious Disease Journal|January 10, 2009
Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccineMatthew D Snape, Jenny M Maclennan, Stephen Lockhart, et al.
Tuberculosis (Edinburgh, Scotland)|December 24, 2013
Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure conceptRoxana Rustomjee, Stephen Lockhart, Jacqueline Shea, et al.
Plos One|September 18, 2014
Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccineMookkan Prabakaran, Sonja Leyrer, Fang He, et al.
Vaccine|April 1, 2008
Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infantsRong Cheng Li, Feng Xiang Li, Yan Ping Li, et al.
Nature Communications|December 15, 2021
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adultsMiwa Haranaka, James Baber, Yoichiro Ogama, et al.
Vaccine|June 19, 2017
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in ItalyAlessandro Zanetti, Maria Giuseppina Desole, Luisa Romanò, et al.
Open Forum Infectious Diseases|December 8, 2025
T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in ChildrenIsabel Vogler, Stephanie Renken, Rolf Hilker, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Therapeutic Drug Monitoring|December 1, 2004
Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometryBrian G Keevil, Sheila Newman, Stephen Lockhart, et al.
Vaccine|August 9, 2021
A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in IndiaJugesh Chhatwal, Amita Sapru, Balasubramanian Sundaram, et al.
Vaccine|July 28, 2020
Preventing infectious diseases for healthy ageing: The VITAL public-private partnership projectDebbie Van Baarle, Kaatje Bollaerts, Giuseppe Del Giudice, et al.
The Pediatric Infectious Disease Journal|January 10, 2009
Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccineMatthew D Snape, Jenny M Maclennan, Stephen Lockhart, et al.
Tuberculosis (Edinburgh, Scotland)|December 24, 2013
Novel licensure pathways for expeditious introduction of new tuberculosis vaccines: a discussion of the adaptive licensure conceptRoxana Rustomjee, Stephen Lockhart, Jacqueline Shea, et al.
Plos One|September 18, 2014
Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccineMookkan Prabakaran, Sonja Leyrer, Fang He, et al.
Vaccine|April 1, 2008
Safety and immunogenicity of a 7-valent pneumococcal conjugate vaccine (Prevenar): primary dosing series in healthy Chinese infantsRong Cheng Li, Feng Xiang Li, Yan Ping Li, et al.
Nature Communications|December 15, 2021
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adultsMiwa Haranaka, James Baber, Yoichiro Ogama, et al.
Vaccine|June 19, 2017
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in ItalyAlessandro Zanetti, Maria Giuseppina Desole, Luisa Romanò, et al.
Open Forum Infectious Diseases|December 8, 2025
T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in ChildrenIsabel Vogler, Stephanie Renken, Rolf Hilker, et al.
Pageof 4